HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The combination of vinorelbine with weekly trastuzumab has produced high response rate in
HER2 overexpressing metastatic breast cancer (MBC). The present phase 2 study was planned to
test activity of the same combination, with trastuzumab given every 3 weeks, rather than
weekly.